A comprehensive view of men's health issues. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca, Merck's Lynparza wins EU nod to treat metastatic castration-resistant prostate cancer; 473,000 cases of prostate cancer diagnosed annually in Europe, with 10% to 20% of patients developing CRPC within five years
Published: December 29, 2022 by Indian Pharma Industry: Policies
AstraZeneca and MSD’s Lynparza tablets combined with abiraterone and prednisone or prednisolone now approved in the EU for treatment of metastatic castration-resistant prostate cancer
Published: December 21, 2022 by AstraZeneca AB
AstraZeneca reports FDA has extended PDUFA date by three months; extension to provide time for full review of sNDA for Lynparza olaparib combination with abiraterone, prednisone or prednisolone to treat metastatic castration-resistant prostate cancer
Published: December 15, 2022 by Contify Life Science News
Novartis wins EU approval for Pluvicto lutetium Lu 177 vipivotide tetraxetan radiopharmaceutical drug to treat prostate cancer; drug contains radioactive agent that destroys cancer cells, antibody that binds to prostate-specific membrane antigen
Published: December 13, 2022 by SeeNews Pharmaceuticals
Gillette announces support for Movember campaign, consolidating the mustache as a symbol of men's health in Brazil to boost awareness of diseases such as prostate cancer; campaign features Liverpool goalkeeper Alisson Becker growing a mustache in support
Published: November 28, 2022 by PR Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count